Clinical Trial

Xeltis Hemodialysis Access Graft (aXess) US Study

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
A multi-center, prospective, single-arm, non-randomized, staged, pivotal clinical study to evaluate the safety and performance of the aXess graft in subjects aged 18 and above, diagnosed with end-stage kidney disease, and possessing an estimated glomerular filtration rate (eGFR) less than 20 ml/min, who intend to undergo hemodialysis but are considered unsuitable candidates for fistula creation by the investigating surgeon.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-02; most recent amendment 2025-08-29.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-12-20
Trial Details
NCT Number NCT06494631
Lead Sponsor Xeltis
Conditions End Stage Renal Disease
Enrollment 140 participants
Start Date 2024-11-11
Primary Completion 2028-01 (estimated)
Study Completion 2032-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29